Business

VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm

Acquisition provides Virbac with a leading specialty product, in a growing segment, to improve the quality of life for senior cats.We are delighted to announce the acquisition of an innovative drug from Norbrook to stabilize feline hyperthyroidism. Virbac will ensure the direct distribution of this treatment under the Thyronorm brand in the United Kingdom, Australia, and New Zealand, and under the Felanorm brand in the United States. In Europe, distribution will continue to be managed by Boehrin

Virbac SaDecember 16, 20252
VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm

About this update from Virbac Sa

  About Virbac - Caring for animals together At Virbac, we are constantly exploring new ways to prevent, diagnose and treat the majority of animal pathologies. We develop care, hygiene and nutrition products to offer complete solutions to veterinarians, farmers and pet owners around the world. Our purpose: advancing the health of animals with those who care for them every day, so we can all live better together. More information on corporate.virbac.com Press contacts - Libremullenlowe agency Attachment

View stock analysis, news, and events for Virbac Sa

NorbrookVirbacBoehringer Ingelheimdirect distributionVirbac GroupThyronormendocrine diseaseVirbac Group sales growth

More from Virbac Sa

All Virbac Sa news →